1.60

6.67% 0.10

After Hours: 1.61 0.01 +0.63%

Atai Life Sciences N V (ATAI)

Overview News Price History Option Chain Financials Discussions Forecast

Atai Life Sciences N V stock is traded at $1.60, with a volume of 1.36M. It is up +6.67% in the last 24 hours and up +18.52% over the past month. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

Previous Close:

$1.50

Open:

$1.53

24h Volume:

1.36M

Relative Volume:

0.80

Market Cap:

$270.16M

Revenue:

$314.00K

Net Income/Loss:

$-40.23M

P/E Ratio:

-5.7143

EPS:

-0.28

Net Cash Flow:

$-84.71M

1W Performance:

+5.96%

1M Performance:

+18.52%

6M Performance:

+5.26%

1Y Performance:

-13.51%

1-Day Range:

$1.495

$1.63

1-Week Range:

$1.37

$1.635

52-Week Range:

$1.03

$2.85

Atai Life Sciences N V Stock (ATAI) Company Profile

Name

Atai Life Sciences N V

Sector

Healthcare (1178)

Industry

Biotechnology (678)

Phone

49 89 2153 9035

Address

WALLSTRASSE 16, BERLIN

Employee

Twitter

Next Earnings Date

2024-12-11

Latest SEC Filings

ATAI's Discussions on Twitter

Compare ATAI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATAI Atai Life Sciences N V	1.60	270.16M	314.00K	-40.23M	-84.71M	-0.28
VRTX Vertex Pharmaceuticals Inc	438.40	113.67B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	683.08	74.97B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	665.68	40.50B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	277.16	35.95B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	120.88	29.63B	3.30B	-501.07M	1.03B	-2.1146

Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-24	Reiterated	H.C. Wainwright	Buy
Apr-03-24	Upgrade	Maxim Group	Hold → Buy
Nov-01-22	Initiated	Loop Capital	Buy
Nov-30-21	Initiated	Maxim Group	Buy
Nov-11-21	Initiated	ROTH Capital	Buy
Oct-18-21	Initiated	H.C. Wainwright	Buy
Sep-01-21	Initiated	Jefferies	Buy
Jul-13-21	Initiated	Berenberg	Buy
Jul-13-21	Initiated	Canaccord Genuity	Buy
Jul-13-21	Initiated	Cantor Fitzgerald	Buy
Jul-13-21	Initiated	Citigroup	Buy
Jul-13-21	Initiated	Cowen	Outperform
Jul-13-21	Initiated	Credit Suisse	Outperform
Jul-13-21	Initiated	RBC Capital Mkts	Sector Perform
Jul-08-21	Initiated	Aegis Capital	Buy

View All

Atai Life Sciences N V Stock (ATAI) Latest News

Jan 29, 2025

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst (NASDAQ:ATAI) - Seeking Alpha

Jan 29, 2025

Jan 28, 2025

Atai Life Sciences Reports Positive Topline Results From Alcohol Use Disorder Treatment Study - Marketscreener.com

Jan 28, 2025

atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder - Yahoo Finance

Jan 28, 2025

Jan 25, 2025

Atai Life Sciences N.V. Announces Resignation of Michael Auerbach as Member of the Supervisory Board of Directors and Supervisory Board?s Compensation Committee - Marketscreener.com

Jan 25, 2025

Jan 24, 2025

ATAI Life Sciences supervisory board member resigns - MSN

Jan 24, 2025

ATAI Life Sciences Board Member Resignation and Changes - TipRanks

Jan 24, 2025

Jan 22, 2025

5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.

Jan 22, 2025

Jan 10, 2025

Srinivas Rao Assumes the Role of Sole CEO of Atai Life Sciences N.V -January 10, 2025 at 07:00 am EST - Marketscreener.com

Jan 10, 2025

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health - Yahoo Finance

Jan 10, 2025

Jan 09, 2025

Atai Life Sciences stock target cut, retains buy rating on developments - Investing.com India

Nov 20, 2024

Nov 19, 2024

Oxbridge Re Holdings Among 3 US Penny Stocks To Watch - Simply Wall St

Nov 19, 2024

Nov 15, 2024

RFK and the 'MAHA Trade': Vaccine makers down, psychedelic shares up - Seeking Alpha

Nov 15, 2024

Nov 13, 2024

Atai Life Sciences Advances Psychedelic Treatments in Q3 2024 - TipRanks

Nov 13, 2024

atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - The Manila Times

Nov 13, 2024

Atai Life Sciences N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024

atai Life Sciences Advances Psychedelic Pipeline as FDA Clears DMT Depression Treatment | ATAI Stock News - StockTitan

Nov 13, 2024

Oct 21, 2024

374Water And 2 Other Promising US Penny Stocks To Watch - Yahoo Finance

Oct 21, 2024

Oct 15, 2024

Are ATAI Life Sciences N.V.’shares a good deal? - US Post News

Oct 15, 2024

Insider Sale Alert: ATAI Life Sciences N.V. [ATAI] – Is it Time to sell? - Knox Daily

Oct 15, 2024

atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit - StockTitan

Oct 15, 2024

Oct 11, 2024

Selling Buzz: ATAI Life Sciences N.V. [ATAI] 10% Owner ATAI Life Sciences N.V. sells 2,660,000 shares of the company - Knox Daily

Oct 11, 2024